Abstract:The modern age of drug discovery, which had been slowly gathering momentum during the early part of the twentieth century, exploded into life in the 1940s with the isolation of penicillin and streptomycin. The immense success of these early drug discovery efforts prompted the general view that many infectious diseases would now be effectively controlled and even eradicated. However this initial optimism was misplaced, and pathogens such as multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus present a major current threat to human health. Drug resistance arises through the unrelenting pressure of natural selection, and there is thus a continuing need to identify novel drug targets and develop chemotherapeutics that circumvent existing drug resistance mechanisms. In this Account, we summarize current progress in developing inhibitors of FabI, the NADH-dependent enoyl reductase from the type II bacterial fatty acid biosynthesis pathway (FAS-II), a validated but currently underexploited target for drug discovery. The FabI inhibitors have been divided into two groups, based on whether they form a covalent adduct with the NAD (+) cofactor. Inhibitors that form a covalent adduct include the diazaborines, as well as the front-line tuberculosis drug isoniazid. The NAD adducts formed with these compounds are formally bisubstrate enzyme inhibitors, and we summarize progress in developing novel leads based on these pharmacophores. Inhibitors that do not form covalent adducts form a much larger group, although generally these compounds also require the cofactor to be bound to the enzyme. Using structure-based approaches, we have developed a series of alkyl diphenyl ethers that are nanomolar inhibitors of InhA, the FabI from M. tuberculosis, and that are active against INH-resistant strains of M. tuberculosis. This rational approach to inhibitor development is based on the proposal that high-affinity inhibition of the FabI enzymes is coupled to the ordering of a loop of amino acids close to the active site. Compounds that promote loop ordering are slow onset FabI inhibitors with increased residence time on the enzyme. The diphenyl ether skeleton has also been used as a framework by us and others to develop potent inhibitors of the FabI enzymes from other pathogens such as Escherichia coli, S. aureus, and Plasmodium falciparum. Meanwhile chemical optimization of compounds identified in high-throughput screening programs has resulted in the identification of several classes of heteroaromatic FabI inhibitors with potent activity both in vitro and in vivo. Finally, screening of natural product libraries may provide useful chemical entities for the development of novel agents with low toxicity. While the discovery that not all pathogens contain FabI homologues has led to reduced industrial interest in FabI as a broad spectrum target, there is substantial optimism that FabI inhibitors can be developed for disease-specific applications. In addition, the availability of genome sequencing data, improved methods for target identification and validation, and the development of novel approaches for determining the mode of action of current drugs will all play critical roles in the road ahead and in exploiting other components of the FAS-II pathway.

Establishment of Screening Model for FabI Inhibitors Based on Antisense RNA Technology

Recombinant Expression of Antimicrobial Peptides in Pichia Pastoris: A Strategy to Inhibit the Penicillium Expansum in Pears

Establishment of high-throughput screening model for β-lactamase inhibitor

Screening of the candidate inhibitory peptides of subtilisin by in vitro RNA display technique

Establishment of Platform for Screening Insulin-Like Growth Factor-1 Receptor Inhibitors and Evaluation of Novel Inhibitors

Characterization Of Anti-Citrinin Specific Scfvs Selected From Non-Immunized Mouse Splenocytes By Eukaryotic Ribosome Display

Group I Intron as a Potential Target for Antifungal Compounds: Development of a Trans-Splicing High-Throughput Screening Strategy

Transcription factor based whole-cell biosensor for inosinic acid in Corynebacterium stationis

A Fast Simplified Fluorescence-Based Method to Screen Specific RNAi Sequence of Connective Tissue Growth Factor

Small Molecule Microarray Screening Methodology Based on Surface Plasmon Resonance Imaging

Screening of inhibitors on successful covalent tyrosinase coupling with help from SpyBank

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway

Establishment of Inhibitor Screening and Validation System for Tryptophanyl Trna Synthetase Using Surface Plasmon Resonance.

Establishment and Application of a High-throughput Drug Screening Assay Targeting Macrophage Migration Inhibitory Factor

Establishment and Application of Cell Model with Stable Expression of hPepT1

Construction of an effective screening system for detection of Pseudomonas aeruginosa quorum sensing inhibitors and its application in bioautographic thin-layer chromatography

Design,synthesis and Activity Evaluation of Small Interfering RNA Targeting Connective Tissue Growth Factor

Identification of Antimicrobial Targets Using a Comprehensive Genomic Approach.

Establishment of a Biosensor-based High-Throughput Screening Platform for Tryptophan Overproduction

Epitope-tagged protein-based artificial miRNA screens for optimized gene silencing in plants

Effective Natural Inhibitors Targeting IGF-1R by Computational Study